4.1 Therapeutic indications
Co-amilozide Tablets are indicated for the treatment of hypertension, congestive heart failure or hepatic cirrhosis with ascites in whom potassium depletion might be anticipated. The presence of amiloride hydrochloride minimises the likelihood of excessive potassium loss during vigorous diuresis for long term therapy. The combination is particularly indicated in conditions where potassium balance is especially important, e.g. in patients with congestive heart failure receiving digitalis.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Cardiovascular Metabolism Learning Zone
Type 2 diabetes and hypertension are independent risk factors for the development of cardiovascular disease which are associated with significant increases in morbidity and mortality. However, recent years have seen a substantial advance in both our understanding of the underlying pathophysiology of these conditions, but also in the management of both diseases.
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).